Drug Treatment of Pain in Patients with Urological Cancers

REFERENCES

• Bonica JJ. Introduction. Acta Anaesthesiol Scand 1982; Suppl. 74: 5–10.
   Google Scholar
• Bonica JJ. Treatment of cancer pain: Current status and future trends. In: Fields HL. ed. Advances in pain research and therapy. Vol. 9. New York: Raven Press, 1985: 589–616.
   Google Scholar
• Tønnessen TI. Control of pain and other symptoms in cancer patients. New York: Hemisphere Press, 1989.
   Google Scholar
• Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84–95.
   PubMed Web of Science ®Google Scholar
• Bonica JJ. Evolution and current status of pain programs. J Pain Symptom Manage 1990; 5: 368–374.
   PubMedGoogle Scholar
• Fields HL. Pain. New York: McGraw-Hill, 1987.
   Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature 1971; 231: 232–235.
   Web of Science ®Google Scholar
• Ferreira SH. Prostaglandins, Aspirin-like drugs and Anal gesia. Nature New Biol 1972; 240: 200–203.
   PubMedGoogle Scholar
• Wall PD, Gutnick M. Ongoing activity in peripheral nerves: 2. The physiology and pharmacology of impulses originating in neuroma. Exp Neurol 1974; 43: 580–593.
   PubMed Web of Science ®Google Scholar
• Kirk EJ. Impulses in the dorsal spinal nerve rootlets in cats and rabbits arising from dorsal root ganglia isolated from the periphery. J Comp Neurol 1974; 2: 165–176.
   Google Scholar
• Malliani A, Pagani M, Lombardi F. Visceral versus somatic mechanisms. In: Wall PD, Melzack R, eds. Textbook of Pain. London: Churchill Livingstone, 1989: 128–137.
   Google Scholar
• Merskev H, Boyd D. Emotional adjustment and chronic pain. Pain 1978; 5: 173–178.
   PubMedGoogle Scholar
• Melzack R, Wall PD. Pain mechanisms – A new theory. Science 1965; 150: 971–979.
   PubMed Web of Science ®Google Scholar
• Fields HL. Pain modulation: opiates and chronic pain. NIDA Res Monogr 1989; 95: 92–101.
   PubMedGoogle Scholar
• Sabbe MB, Yaksh TL. Pharmacology of spinal opioids. J Pain Symptom Manage 1990; 5: 191–203.
   PubMedGoogle Scholar
• Waldman SD, Yaksh TL. Spinal opioids: historical perspectives and future directions. Introduction. J Pain Symptom Manage 1990; 5: 137.
   PubMedGoogle Scholar
• Merskey H. Psychiatry and chronic pain: see comments. Can J Psychiatry 1989; 34: 329–336.
   PubMed Web of Science ®Google Scholar
• Coyle N. Continuity of care for the cancer patient with chronic pain. Cancer 1989; 63 Suppl.: 2289–2293.
   PubMedGoogle Scholar
• Magni G, Merskey H. Psychological factors associated with chronic pain. Presse Med 1989; 18: 770–775.
   PubMedGoogle Scholar
• Foley KM. Controversies in cancer pain: Medical perspectives. Cancer 1989; Suppl. 63: 2257–2265.
   PubMedGoogle Scholar
• Daut RL, Cleeland CS. The prevalence and severity in cancer. Cancer 1982; 50: 1913–1918.
   PubMed Web of Science ®Google Scholar
• Twycross RG, Fanfield S. Pain in far advanced cancer. Pain 1982; 14: 303–310.
   PubMed Web of Science ®Google Scholar
• Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990; 5: 83–93.
   PubMedGoogle Scholar
• Twycross RG, Lack SA. Symptom control in far advanced cancer: Pain relief. London: Pitman Publ. Ltd., 1983.
   Google Scholar
• McKillop JH, McDougall IR. The role of skeletal scanning in clinical oncology. Br Med J 1980; 281: 407–409.
   PubMedGoogle Scholar
• Hart FC, Huskisson EC. Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use. Drugs 1984; 27: 232–255.
   PubMed Web of Science ®Google Scholar
• Kanner RM. Pharmacological management of pain and symptom control in cancer. J Pain Symptom Manage 1987; 2: S19–S22.
   PubMedGoogle Scholar
• Forgac M, Cantley L, Wiedemann B, Altstiel L, Branton D. Chlathrin-coated vesicles contain an ATP-dependent proton pump. Proc Natl Acad Sci USA, 1983; 80: 1300–-1303.
   PubMed Web of Science ®Google Scholar
• Karmali RA. Eicosanoids and cancer. Prog Clin Biol Res 1986; 222: 687–697.
   PubMedGoogle Scholar
• Tannock I, Gaspodarowicz, M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisolone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590–597.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Scher HI, Forman JD, Linares LA, Curley T, Fuks Z. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens. Int J Radiat Oncol Biol Phys 1989; 17: 1281–1285.
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Nielsen OS, Klee M, R:rth M. Palliative irradiation of bone metastases. Cancer Treat Rev 1989; 16: 41–48.
   PubMedGoogle Scholar
• Friedl W. Indication, management and results of surgical therapy of pathological fractures in patients with bone metastases. Eur J Surg Oncol 1990; 16: 380–396.
   PubMedGoogle Scholar
• Elliott K, Foley KM. Neurologic pain syndromes in patients with cancer. Crit Care Clin 1990; 6: 393–420.
   PubMedGoogle Scholar
• Elliott K, Foley KM. Neurologic pain syndromes in patients with cancer. Neurol Clin 1989; 7: 333–360.
   PubMed Web of Science ®Google Scholar
• Brahm J. Temperature-dependent changes of chloride transport kinetics in human red cells. J Gen Physiol 1977; 70: 283–307.
   PubMedGoogle Scholar
• Esteban A, Traba A. Post-radiation brachial plexus disease. Clinical and neurophysiological study. Arch Neurobiol (Madr) 1990; 53: 23–32.
   PubMedGoogle Scholar
• Ebner I, Anderl H, Mikuz G, Frommhold H. Plexus neuropathy: tumor infiltration or radiation damage. ROFO 1990; 152: 662–666.
   PubMedGoogle Scholar
• Ventafridda V, Ripamonti C, De Conno F, Tamburini M, Cassileth BR. Symptom prevalence and control during cancer patients' last days of life. J Palliat Care 1990; 6: 7–11.
   PubMedGoogle Scholar
• Ventafridda V, De Conno F, Panerai AE, Maresca V, Monza GC, Ripamonti C. Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs. J Int Med Res 1990; 18: 21–29.
   PubMed Web of Science ®Google Scholar
• Rane A, Säwe J, Dahlström B, Paalzow L, Kager L. Pharmacological treatment of cancer pain with special reference to the oral use of morphine. Acta Anaesthesiol Scand Suppl 1982; 74: 97–103.
   PubMedGoogle Scholar
• Säwe J, Dahlström B, Paalzow L, Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther 1981; 30: 629–635.
   PubMed Web of Science ®Google Scholar
• Säwe J, Kager L, Svensson Eng JO, Rane A. Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. Br J Clin Pharmacol 1985; 19: 495–501.
   PubMed Web of Science ®Google Scholar
• Säwe J, Dahlström B, Rane A. Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol 1983; 24: 537–542.
   PubMed Web of Science ®Google Scholar
• Poulain P, Hoskin PJ, Hanks GW, A-Omar O, Walker VA, Johnston A, Turner P, Aherne GW. Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients. Br J Anaesthesia 1988; 61: 569–574.
   PubMed Web of Science ®Google Scholar
• Arkinstall WW, Goughnous BR, White JA, Stewart JH. Control of severe pain with sustained-release morphine tablets v. oral morphine solution. Can Med Ass J 1989; 140: 653–664.
   Google Scholar
• Thirlwell MP, Sloan PA, Maroun JA, Boos GJ, Besner J-G, Stewart JH, Mount BM. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989; Suppl. 63: 2275–2283.
   PubMedGoogle Scholar
• Portenoy RK, Maldonado M, Fitzmartin R, Kaiko RF, Kanner R. Oral controlled-release morphine sulfate: Analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients. Cancer 1989; Suppl. 63: 2284–2288.
   PubMedGoogle Scholar
• Goughnour BR, Arkinstall WW, Stewart JH. Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients. Cancer 1989; Suppl. 63: 2294–2297.
   PubMedGoogle Scholar
• Kaiko RF, Grandy RP, Oshlack B, Pav J, Horokniak J, Thomas G, Ingber E, Goldenheim PD. The United States experience with oral controlled-release morphine (MS contin tablets): Parts I and II. Review of nine dose titration studies and clinical pharmacology of 15 mg, 30 mg, 60 mg and 100 mg tablets strengths in normal subjects. Cancer 1989; Suppl. 63: 2348–2354.
   PubMedGoogle Scholar
• Warfield CA. Evaluation of dosing guidelines for the use of oral controlled-release morphine (MS Contin tablets). Cancer 1989; Suppl. 63: 2360–2364.
   PubMedGoogle Scholar
• Hanks GW. Controlled-release morphine (MST Contin) in advanced cancer: The European experience. Cancer 1989; Suppl. 63: 2378–2382.
   PubMedGoogle Scholar
• Walsh TR. Controlled study of slow release morphine for chronic pain in advanced cancer. Pain 1984; Suppl. 2: S202.
   Google Scholar
• Lapin J, Houde RW, Kaiko RF, Coyle N, Rogers A, Foley KM. Cancer pain management with a controlled-release oral morphine preparation. J Pain Symptom Manage 1989; 4: 146–151.
   PubMedGoogle Scholar
• Hansen J, Ginman C, Hartvig P, Jakobsson PA, Nilsson MI, Rane A, Säwe J, Anggard E. Clinical evaluation of oral methadone in treatment of cancer pain. Acta Anaesthesiol Scand Suppl. 1982; 74: 124–127.
   PubMedGoogle Scholar
• Säwe J, Hansen J, Ginman C, Hartvig P, Jakobsson PA, Nilsson MI, Rane A, Anggard E. Patient-controlled dose regimen of methadone for chronic cancer pain. Br Med J Clin Res 1981; 282: 771–773.
   PubMed Web of Science ®Google Scholar
• Kort WJ, Hulsman LOM, van Schalkwijk WP, Weijma IM, Zondervan PE, Westbroek DL. Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats. JNCI 1986; 76: 711–720.
   PubMed Web of Science ®Google Scholar
• Flower RJ, Moncada S, Vane JR. Drug therapy of inflammation. Analgesic-antipyretics and anti-inflammatory agents; Drugs employed in the treatment of gout. In: Goodman Gilman A, Goodman LS, Rall TW, Murad F, eds. The pharmacological basis of therapeutics. N. Y,: Macmillan Publishing Company, 1985: 674–715.
   Google Scholar
• Cleton FJ, van Holten-Verzantvoort AT, Bijvoet OL. Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results Cancer Res 1989; 116: 73–78.
   PubMedGoogle Scholar
• Arner S. The role of nerve blocks in the treatment of cancer pain. Acta Anaesthesiol Scand 1982; Suppl. 74: 104–108.
   Google Scholar
• Cousins MJ, Gourlay GK, Cherry DA, Plummer JL. Treatment of cancer pain with orally and spinally administered opioids. Aust N Z J Surg 1989; 59: 307–315.
   PubMedGoogle Scholar
• Tanelian DL, Cousins MJ. Combined neurogenic and nociceptive pain in a patient with Pancoast tumor managed by epidural hydromorphone and oral carbamazepine. Pain 1989; 36: 85–88.
   PubMedGoogle Scholar
• Meyerson B. The role of neurosurgery in the treatment of cancer pain. Acta Anaesth Scand 1982; Suppl. 74: 109–113.
   Google Scholar